PMI Biopharma Solutions, a provider of research, pharmaceutical development, and early-phase clinical manufacturing services and Nashville Biosciences, a clinical-genomic and bioinformatics company, have formed a drug discovery and development collaboration.
 
Under this alliance, both organizations will have the opportunity to bundle Nashville Bioscience’s data and in silico technology with PMI’s comprehensive laboratory services and scientific expertise to experimentally test mechanistic and therapeutic hypotheses for a comprehensive drug target identification and validation package.
 
“With both organizations located in Nashville it was an easy decision to pair our capabilities to better serve our clients,” said David Sunseri, chief executive officer, PMI Biopharma Solutions. “This alliance will allow clients a smooth transition from in silico to in vitro studies.”
 
Leeland Ekstrom, chief operating officer and founder of Nashville Biosciences, said, “Our respective capabilities fit together very nicely to advance our clients’ research & development in the life sciences. We are excited to collaborate with PMI Biopharma Solutions to better serve our clients.”